[Click eStock] "IMBDX, Abundant Momentum for Additional Upside"

Korea Investment & Securities analyzed on the 1st that attention should be paid to the export expansion trend of IMBDX. No investment opinion or target price was presented.

Si-on Kang, a researcher at Korea Investment & Securities, explained, "IMBDX's flagship product is ‘AlphaLiquid100’ for patients with stage 3-4 solid tumors," and "it drove overall performance with sales of 2.3 billion KRW last year." He added, "Domestic sales growth may be somewhat moderate this year due to the impact of medical strikes," but "export growth is expected to offset this."

Researcher Kang analyzed, "Sales in Thailand are steady following Taiwan," and "market entry into Japan and India will be concretized in the second half of this year." He emphasized, "Sales of AlphaLiquid HRR are expected to increase from 339 prescriptions last year to at least 1,400 this year," and "this will expand sales contributions."

Researcher Kang explained, "It is too early to expect rapid short-term growth for the Detect and Find products," but "there is sufficient momentum to positively affect the stock price." He also explained, "CancerDetect is currently used only for research purposes in a limited way," and "an application for new medical technology evaluation is scheduled within this month."

Upon registration as a new medical technology, the market is expected to expand to general services, leading to full-scale sales growth. Researcher Kang introduced that CancerFind, targeting the general public, has the highest growth potential among the products. He stated, "Attention is paid to expanding diagnostic cancer types and market penetration through strategic pricing." He added, "Overhang volume is being gradually absorbed," but advised, "Considering the remaining shares, overhang risk remains."

This content was produced with the assistance of AI translation services.